GB1595234A - Thienamycin derivatives - Google Patents
Thienamycin derivatives Download PDFInfo
- Publication number
- GB1595234A GB1595234A GB5077/78A GB507778A GB1595234A GB 1595234 A GB1595234 A GB 1595234A GB 5077/78 A GB5077/78 A GB 5077/78A GB 507778 A GB507778 A GB 507778A GB 1595234 A GB1595234 A GB 1595234A
- Authority
- GB
- United Kingdom
- Prior art keywords
- fractions
- composition
- amidohydrolase
- combined
- deionized water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- WKDDRNSBRWANNC-ATRFCDNQSA-N Thienamycin Chemical class C1C(SCCN)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 WKDDRNSBRWANNC-ATRFCDNQSA-N 0.000 title description 3
- 230000003115 biocidal effect Effects 0.000 claims abstract description 31
- 150000001875 compounds Chemical class 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 102000004190 Enzymes Human genes 0.000 claims abstract description 8
- 108090000790 Enzymes Proteins 0.000 claims abstract description 8
- 125000003047 N-acetyl group Chemical group 0.000 claims abstract description 7
- 230000003301 hydrolyzing effect Effects 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 22
- 108090000531 Amidohydrolases Proteins 0.000 claims description 21
- 102000004092 Amidohydrolases Human genes 0.000 claims description 21
- 239000000725 suspension Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 19
- 239000008367 deionised water Substances 0.000 claims description 17
- 229910021641 deionized water Inorganic materials 0.000 claims description 17
- PVCJKHHOXFKFRP-UHFFFAOYSA-N N-acetylethanolamine Chemical compound CC(=O)NCCO PVCJKHHOXFKFRP-UHFFFAOYSA-N 0.000 claims description 14
- 244000005700 microbiome Species 0.000 claims description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 241000586779 Protaminobacter Species 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000003242 anti bacterial agent Substances 0.000 claims description 7
- 229940088710 antibiotic agent Drugs 0.000 claims description 7
- -1 elixir Substances 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 230000000975 bioactive effect Effects 0.000 claims description 6
- 235000008504 concentrate Nutrition 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000003973 paint Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 3
- 238000005481 NMR spectroscopy Methods 0.000 claims description 3
- 238000002835 absorbance Methods 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 3
- 235000019270 ammonium chloride Nutrition 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 229930003347 Atropine Natural products 0.000 claims description 2
- 240000008100 Brassica rapa Species 0.000 claims description 2
- 229930182566 Gentamicin Natural products 0.000 claims description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical group O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims description 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims description 2
- 229960000396 atropine Drugs 0.000 claims description 2
- 229920001429 chelating resin Polymers 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000000645 desinfectant Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 claims description 2
- 229960004192 diphenoxylate Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 239000006193 liquid solution Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 239000002609 medium Substances 0.000 description 19
- 239000000243 solution Substances 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 229910001868 water Inorganic materials 0.000 description 13
- 239000000872 buffer Substances 0.000 description 11
- 229940041514 candida albicans extract Drugs 0.000 description 7
- 239000012138 yeast extract Substances 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000007836 KH2PO4 Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 5
- 235000019796 monopotassium phosphate Nutrition 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 239000008121 dextrose Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000037230 mobility Effects 0.000 description 4
- 239000006916 nutrient agar Substances 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 239000002689 soil Substances 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 241001453268 Comamonas terrigena Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000588767 Proteus vulgaris Species 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000005842 biochemical reaction Methods 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000003381 deacetylation reaction Methods 0.000 description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 3
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 3
- 235000019797 dipotassium phosphate Nutrition 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000008057 potassium phosphate buffer Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229940007042 proteus vulgaris Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- HWEXKRHYVOGVDA-UHFFFAOYSA-M sodium;3-trimethylsilylpropane-1-sulfonate Chemical compound [Na+].C[Si](C)(C)CCCS([O-])(=O)=O HWEXKRHYVOGVDA-UHFFFAOYSA-M 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- 241000588770 Proteus mirabilis Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000012474 bioautography Methods 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 230000006196 deacetylation Effects 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 238000002834 transmittance Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 241000588779 Bordetella bronchiseptica Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241001453233 Doodia media Species 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Natural products O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 108010048581 Lysine decarboxylase Proteins 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000515012 Micrococcus flavus Species 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 1
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241001148142 Pectobacterium atrosepticum Species 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 241000364057 Peoria Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000589614 Pseudomonas stutzeri Species 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 241000872198 Serjania polyphylla Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000958211 Streptomyces flavogriseus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000035425 carbon utilization Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000013048 microbiological method Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 230000014075 nitrogen utilization Effects 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000013587 production medium Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- YCUVUDODLRLVIC-VPHDGDOJSA-N sudan black b Chemical compound C1=CC(=C23)NC(C)(C)NC2=CC=CC3=C1\N=N\C(C1=CC=CC=C11)=CC=C1\N=N\C1=CC=CC=C1 YCUVUDODLRLVIC-VPHDGDOJSA-N 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015113 tomato pastes and purées Nutrition 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
- C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
- C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
- C07D477/20—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/182—Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system
- C12P17/184—Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system containing a beta-lactam ring, e.g. thienamycin
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Antibiotic deacetyl 890A10 of the structure <IMAGE> and its pharmaceutically acceptable salts; it is produced from the compound 890A10 of the structure <IMAGE> by treatment with an enzyme which is capable of hydrolysing the N-acetyl group.
Description
(54) THIENAMYCIN DERIVATIVES
(71) We, MERCK & CO. INC., a corporation duly organized and existing under the laws of the State of New Jersey, United States of America, of Bahway, New Jersey, United
States of America, do hereby declare the invention for which we pray that a patent may be granted to us and the method by which it is to be performed to be particularly described in and by the following statement:
The discovery of the remarkable antibiotic properties of penicillin stimulated great interest in this field which has resulted in the finding of many other valuable antibiotic substances such as other penicillins, streptomycin, bacitracin, tetracyclines, chloramphenicol and erythromycins. In general, the antibacterial activity of each of these antibiotics does not include certain clinically important pathogenic bacteria. For example, some are principally active against only gram-positive types of bacteria. Acquired resistance over the course of widespread use of existing antibiotics in the treatment of bacterial infection has caused a serious resistance problem to arise.
Accordingly, the deficiencies of the known antibiotics have stimulated further research to find other antibiotics which will be active against a wider range of pathogens as well as resistant strains of particular microorganisms.
This invention provides the new antibiotic desacetyl 890A1(), including its pharmaceutically acceptable salts. The invention encompasses the antibiotic in dilute forms, as crude concentrates and in pure forms. It also provides a composition comprising an antibacterially effective amount of the compound desacetyl 890A1() and a non-toxic pharmaceutically acceptable carrier, and a composition comprising an antibacterially effective amount of desacetyl 890A,(, and a carrier or diluent.
It has been found that desacetyl 890at() is highly effective in inhibiting the growth of various gram-negative and gram-positive microorganisms.
In accordance with the present invention, desacetyl 890Al() is produced by hydrolysing the N-acetyl group of 890at() using an amidohydrolase capable of hydrolysing the N-acetyl group. A convenient source of an amidohydrolase with this capability is amidohydrolaseproducing strains of the microorganism Protaminobacter rube. The particular enzyme produced by Protaminobacter ruber is N-acetyl-890Al() amidohydrolase, a member of the sub-group of enzymes designated E.C. 3.5.1 according to the recommended enzyme nomenclature of the International Union of Pure and Applied Chemistry and the
International Union of Biochemistry.
The microorganism capable of carrying out the deacetylation process was isolated from a soil sample and, based upon taxonomic studies, was identified as belonging to the species
Protaminobacter ruber and has been designated MB-3528 in the culture collection of
MERCK & CO., Inc., Rahway, New Jersey. A culture thereof has been placed on unrestricted permanent deposit with the culture collection of the Northern Regional
Research Laboratories, Northern Utilization Research and Development Division,
Agricultural Research Service, U.S. Department of Agriculture, Peoria, Illinois, and has been assigned accession No. NRRL B-8143.
The morphological and cultural characteristics of Protaminobacter ruber NRRL B-8143 as well as carbon and nitrogen utilization and biochemical reactions are as follows: Morphology - Cells are rod-shaped with rounded ends, 0.9-1.2 x 2.4-4.6 microns, occurring singly or in pairs. Twenty-four and forty-eight hour cells stain gam-negative with a granular appearance. The granules, especially the polar granules, stain black with Sudan
Black B. Cells are motile at 28"C., but motility is questionable at 370C.
Cultural Characteristics - Nutrient agar colonies are at first thin, punctiform, semitransparent and colorless; then becoming low convex, opaque, smooth, edge entire, somewhat dry in consistency and pigmented rose to rose-red.
Nutrient broth cultures are uniformly turbid with no pellicle.
Pigment production is not dependent on light or temperatures tested (28"C. and 37"C.).
Pigment is soluble in acetone but insoluble in water or chloroform.
Growth on nutrient agar and brain-heart infusion agar under aerobic conditions is somewhat slow but good at 28"C.; growth is moderate to good but slower at 370C.; there is no growth at 50"C.
Utilization of Carbon and Nitrogen Sources
Using a basal salts medium with ammonium sulfate as nitrogen source, growth is good with arabinose, moderate with xylose, and poor with dextrose, fructose, mannose, rhamnose, lactose, maltose, sucrose, raffinose, cellulose, inositol and mannitol.
N-acetylethanolamine can be utilized as the sole carbon and nitrogen source.
No acid or gas is produced from dextrose or lactose in OF Basal Medium (Difco
Laboratories, Detroit, Michigan) under aerobic or anaerobic conditions.
Biochemical Reactions
The biochemical reactions are based on standard methods as described in Manual of
Microbiological Methods, edited by the Society of American Bacteriologists, McGraw-Hill
Book Co., New York, 1957.
Catalase - positive
Oxidase - negative
Starch not hydrolyzed
Casein not hydrolyzed
Gelatin not liquefied
Litmus milk unchanged in consistency but becomes slightly alkaline after 7 days.
Indol - negative
H2S - negative
Nitrates not reduced
Urease - positive
Lysine and ornithine decarboxylase - negative.
890A,o is the term applied to the antibiotic having the formula
890A,,, its description and processes of production are set forth in the specification of our copending application No. 47324/77 (Serial No 1595233).
The novel antibiotic of the present invention, desacetyl 890at,), has the structural formula
and is prepared by enzymatic hydrolysis of 890A1(), using an amidohydrolase present in species of genus Protaminobacter.
The novel process of the present invention involves the cleavage of the N-acetyl group of the compound of the formula:
by intimately contacting the said compound with an amidohydrolase capable of hydrolysing the N-acetyl group. More specifically, the process of the present invention provides for the
N-deacetylation of 890A,(, by intimately contacting said compound with the amidohydrolase, N-acetyl-890A1 amidohydrolase.
By an unexpected homology between N-acetylethanolamine and 89()A1(), extracts of microorganisms with the enzyme N-acetylethanolamine amidohydrolase arc in many cases able to hydrolyse 890at().
The compound 89()A1() is prepared by the fermentation of broth with the microorganism
Streptomyces flavogriseus.
In the detailed description and examples that follow, the words "Dowex", "Whatman", "Eastman", "Chromagram", "Difco", "Hyflo", "Super-Cel", "Amberlitc" and "XAD" are trade marks. Parts are by weight unless otherwise indicated. Mesh sizes in the examples are U.S. standards.
Physical and Chemical Properties of Desacetyl 890ago Table 1 lists the antibacterial spectrum profile of desacetyl 890also TABLE I
ASP# Organism, MB# (ATCC#) Inhib. Zone Diam., mm
1 Bacillus sp. 633 28
2 Proteus vulgaris 1012 5
3 Pseudomonas aeruginosa 979 0
4 Serratia marcescens 252 (990) 9
5 Staphylococcus aureus 108 (6538 P) 23
6 Bacillus subtilis 964 (6633) 31
7 Sarcina lutea 1101 21
8 Staphylococcus aureus 698 20
9 Streptococcus faecalis 753 0 10 Brucella bronchiseptica 965 (4617) 0 11 Vibrio percolans 1272 (8461) 27 12 Proteus vulgaris 838 (21100) 14 13 Escherichia coli 1418 12 14 Pseudomonas stutzeri 1231 (11607) 16 15 Klebsiella pneumoniae 1264 8 16 Aerobacter aerogenes 835 9 17 Erwinia atroseptica 1159 (4446) 11 18 Pseudomonas aeruginosa 2824 14H 19 Corynebacterium pseudodiph 261 (9742) 14 20 Escherichia coli 60 (9637) 10 21 Streptococcus faedum 2820 0 22 Streptococcus agalactiae 2875 23 23 Proteus vulgaris 2112 (episome) 15 24 Proteus mirabilis 3126 0 25 Vibrio percolans 1272 + 2 x 105 u/ml 10
penicillinase 26 V. percolans 1272 + Lactamase from
Enterobacter MB2646 28 27 Micrococcus flavus 369 (10240) 17
Table 2 lists the 300 MHz nuclear magnetic resonance (NMR) spectra signal of deacetylated 890Alo determined relative to internal standard DSS (sodium 2,2-dimethyl-2silapentane-5-sulfonate) in D2O (24"C.).
TABLE 2
H 58 CH3 1.51 (6.2)b
3.14 3.43 3.07 (18.0,8.5) 3.43 (18.0,9.0)
H6 3.88 (5.6,8.9)
H5 4.36
H8 4.7-4.9(estimated)
"shifts relative to calculated position of internal DSS
bvalues in parenthesis are coupling constants.
The mobility of deacetylated 890A,o is determined on Dowex-1. Approximately 100 ssg of desacetyl 890A1() is applied to a column (0.7 x 15 cm.) of Dowex-1 x 2 (Cl-), 200-400 mesh, at an ionic strength of less than 0.01 M and is eluted with a solution containing 0.10 M NaCI + 0.011 M NH4Cl + 0.0001 M NH3 at pH 7.2 in deionized water. The main peak of desacetyl 890A() occurs between eluted volumes 65 ml. and 124 ml. with a maximum at eluted volume 109 ml.
Desacetyl 890A", has a maximum absorbance in the ultraviolet spectra at 296 nm.
The mobility of desacetyl 890A1() is determined on thin layer chromatography and electrophoresis.
Upon thin layer chromatography of desacetyl 890A,(, on Eastman Chromagram 6064 cellulose sheets at 230C. in 66% (v/v) ethanol, the antibiotic displays an Rf of 0.68 as measured by bioautography.
Upon electrophoresis of desacetyl 890A,() on Whatman 3MM chromatography paper using a buffer containing 35.2 g. KH2PO4 + 57.2 g. Na2HPO4 per liter, at 47 volts/cm. for 50 minutes, antibiotic desacetyl 890A,(, moved .65 mm. toward the positive electrode.
Under the same conditions, antibiotic 890A,(, moved 118 mm. toward the positive electrode. The mobilities are measured by bioautography, using chloramphenicol as a reference marker whose mobility is assumed to be zero.
Desacetyl 890A1(), the compound of this invention is a valuable antibiotic active against various gram-positive and gram-negative bacteria and, accordingly, finds utility in human and veterinary medicine. The compound of this invention can be used as an antibacterial drug for treating infections caused by gram-positive or gram-negative bacteria, for example against susceptible strains of Staphylococcus aureus, Proteus mirabilis, Escherichia coli.
Klebsiella pneumoniae, Enterobacter cloacae and Pseudomonas aeruginosa. The antibacterial material of the invention may further be utilized as an additive to animal feeding-stuffs for preserving foodstuffs and as a disinfectant. For example, it may be used in aqueous compositions in concentrations ranging from 0.1 to 100 parts of antibiotic per million parts of solution or preferably in concentrations ranging from 1 to 10 parts of antibiotic per million parts of solution in order to destroy and inhibit the growth of harmful bacteria on medical and dental equipment and as bactericides in industrial applications, for example in water-based paints and in the white water of paper mills to inhibit the growth of deleterious bacteria.
The antibiotic of this invention may be used in any one of a variety of pharmaceutical preparations as the sole active ingredient or in combination either with one or more other antibiotics or with one or more pharmacologically active substances. As an example of the former, an aminocyclitol antibiotic such as gentamicin may be coadministered in order to minimize any chance that resistant organisms will emerge. As an example of the latter, diphenoxylate and atropine may be combined in dosage forms intended for the therapy of gastroenteritis. The antibiotic may be used in capsule form or as tablets, powders or liquid solutions or as suspensions or elixirs. It may be administered orally, topically, intravenously or intramuscularly.
Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example, syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example, lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; lubricants, for example, magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example, potato starch, or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to well known methods. Oral liquid preparations may be in the form of aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product, for reconstitution with water or other suitable vehicles before use. Such liquid preparations may contain conventional additives such as suspending agents, for example, sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate or acacia; nonaqueous vehicles, which may include edible oils, for example, almond oil or fractionated coconut oil, oily esters, propylene glycol or ethyl alcohol; preservatives, for example methyl or propyl phydroxybenzoates, or sorbic acid. Suppositories will contain conventional suppository bases, e.g. cocoa butter or other glyceride.
Compositions for injection may be presented in unit dose form in ampoules, or in multidose containers with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g.
sterile pyrogen-free water, before use.
The compositions may also be prepared in suitable forms for absorption through the mucous membranes of the nose and throat or bronchial tissues and may conveniently take the form of powder or liquid sprays or inhalants, lozenges or throat paints. For medication of the eyes or ears, the preparations may be presented as individual capsules, in liquid or semi-solid form, or may be used as drops. Topical applications may be formulated in hydrophobic or hydrophilic bases as ointments, creams, lotions, paints or powders.
Also, in addition to a carrier, the compositions of the present invention may include other ingredients such as stabilizers, binders antioxidants, preservatives, lubricators, suspending agents, viscosity agents or flavoring agents.
In veterinary medicine, such as in the treatment of cows, sheep and pigs, the compositions may, for example, be formulated as intramammary preparations in either long-acting or quick-release bases. They can also be used for treating chickens.
The dosage to be administered depends to a large extent upon the condition of the subject being treated, the weight of the host, the type of infection and the route and frequency of administration, the parenteral route being preferred for generalized infections and the oral route for intestinal infections.
In the treatment of bacterial infections in man, the compound of this invention is administered orally or parenterally, in accordance with conventional procedures for antibiotic administration, in an amount of from 2 to 600 mg./kg./day and preferably 5 to l()() mg./kg./day in preferably divided dosage, e.g. three to four times a day. It may be administered in dosage units containing, for example, 25, 250, 330, 400 or 1000 mg. of active ingredient with suitable physiologically acceptable carriers or excipients. The dosage units are in the form of liquid preparations such as solutions or suspensions or as solids in tablets or capsules. It will, of course, be understood that the optimum dose in any given instance will depend upon the type and severity of infection to be treated, and that smaller doses will be involved in pediatric use, all of such adjustments being within the skill of the practitioner in the field.
The examples, which follow, illustrate the methods by which the products of this invention may be obtained. The examples are illustrative.
EXAMPLE 1
Method of Isolation of N-Acetyl-890A", amidohydrolase-producing Organisms
A 1% (w/v) suspension of fertile lawn soil is prepared by suspending 1 g. of lawn soil in 100 ml. sterile phosphate-buffer-saline solution of the following composition:
Phosphate-Buffer-Saline Solution
NaCI 8.8 g.
1M Phosphate Buffer, pH 7.5* 10 ml.
Distilled H2O 1000 ml.
*IM Phosphate Buffer, pH 7.5
16 ml. 1M KH2PO4 is mixed with 84 ml. 1M K2HPO4.
The pH of the phosphate buffer is adjusted to
7.5 by adding small quantities of either IM KH2PO4
or 1M K2HPO4.
Aliquot portions of this 1% stock soil suspension are used to prepare 10x, 100x and 1,000x dilutions.
One-ml. portions of the stock suspensions or 1-ml. portions of the 10x, 100x, and 1,000x dilutions are added to 2-ml. portions of sterile 1.0% agar solutions at 48"C. The mixtures are quickly poured over the surface of sterile petri dishes of 85 mm. diameter containing 20 ml. of Medium A. Medium A has the following composition:
Medium A
KH2PO4 3.0 g.
K2HPO4 7.0 g.
MgSO4 0.1 g.
Distilled H,O 1000 ml.
N-Acetylethanol
amine solution 8.5 ml.
*N-acetylethanolamine Solution
N-acetylethanolamine is diluted 10x in H2O
and membrane sterilized. This solution is
added after autoclaving.
For solid media: Add 20 g. agar
The petri dishes are incubated for 18 days at 28"C. Well-isolated colonies are picked and streaked on Medium B. Medium B has the following composition:
Medium B
Tomato Paste 40 g.
Ground Oatmeal 15 g.
Distilled H2O 1000 ml.
pH adjusted to 6 using NaOH
For solid media: add 20 g. agar
Individual clones are selected and grown for two days at 28"C. on slants of Medium B.
A portion of the growth of the slants is used to inoculate a 250-ml. Erlenmeyer flask containing 50 ml. of Medium A; a 250-ml. Erlenmeyer flask containing 50 ml.
supplemented Medium B (supplemented after autoclaving with 0.4 ml. of a membranesterilized solution of N-acetylethanolamine diluted 10x with water); and a 250-ml.
Erlenmeyer flask containing 50 ml. Medium C. Medium C has the following composition:
Medium C
Dextrose 20 g.
Pharmamedia 8 g.
Corn Steep Liquor
(wet basis) 5 g.
Distilled H2O 1000 ml.
pH adjusted to 7 with NaOH or HCI
N-acetylethanol
amine solution8 8.5 ml.
*N-acetylethanolamine Solution
N-acetylethanolamine is diluted 10x in H2O and
membrane sterilized. This solution is added
after autoclaving.
The flasks are shaken at 28"C. on a 220 rpm (2" throw) shaker for 4 days. A 30-ml.
portion from each flask is centrifuged for 15 minutes at 8,000 rpm. The supernatant portion is removed, leaving only enough to form a thick suspension of cells and media solids. Half of the suspension is subjected to ultrasonic disruption using a Branson Instrument Model
LS-75 Sonifier with a 1/2 inch probe. The input power is set at position No. 4, and four successive 15-second cycles of irradiation are used, while chilling the suspension in ice water during and between disruption. To test for the presence of N-acetyl-890A lo amidohydrolase activity, a 10-pl. portion of the sonicate is mixed with 25 Fl. of an 890A1() solution containing 500 Fg. per ml. Controls containing antibiotic and buffer alone; and sonicated cells and buffer without antibiotic are also carried out. After incubation overnight at 280C., 10 Fl.
quantities are applied to Schleicher and Schuell No. 2043-B paper. Using 0.03 M potassium phosphate buffer pH 7.1, a voltage gradient of 50 volts/cm. is applied for 30 minutes. The paper is placed on a Staphylococcus aureus ATCC 6538P plate and incubated at 370C. for 18 hours.
The assay plates are prepared as follows: an overnight growth of the assay organism,
Staphylococcus aureus ATCC 6538P, in nutrient broth plus 0.2% yeast extract is diluted with nutrient broth, plus 0.2% yeast extract to a suspension having 60% transmittance at a wavelength of 660 nm. This suspension is added to Difco nutrient agar supplemented with 2.0 g./l. Difco yeast extract at 47"C. to 48"C., to make a composition containing 33.2 ml. of the suspension per liter of agar. Forty ml. of this suspension is poured into 22.5 cm x 22.5 cm. petri plates, and these plates are chilled and held at 4"C. until used (5 day maximum).
The unchanged bioactive 890A,(, spot migrated 8 cm. toward the positive pole. A new bioactive spot due to desacetyl 890A,(, is detected and migrated 4 cm. toward the positive pole. Control incubation mixtures of antibiotic plus buffer, and cell sonicate plus buffer produce no bi6active material migrating 4 cm. toward the positive pole.
EXAMPLE 2 Deacetylation of 890A zo A portion of the growth on a slant of Protaminobacter ruber MB-3528 is used to inoculate a 250-ml. Erlenmeyer flask containing 50 ml. of Medium C. Medium C has the following composition:
Medium C
Dextrose 20 g.
Pharmamedia 8 g.
Corn Steep Liquor
(wet basis) 5 g.
Distilled H2O 1000 ml.
pH adjusted to 7 with NaOH or HCI
N-acetylethanolamine solution 8.5 ml.
*N-acetylethanolamine Solution
N-acetylethanolamine is diluted 10x in H2O and
membrane sterilized. This solution is added
after autoclaving.
The flask is shaken at 28"C. on a 220 rpm (2-inch throw) shaker for four days. A 25-ml.
portion from the flask is centrifuged for 15 minutes at 8,000 rpm. The supernatant is removed and the cells on the surface of the media solids scraped off into 0.5 ml. of 0.05M potassium phosphate buffer, pH 7.4. The resulting suspension is subjected to ultrasonic disruption using a Branson Instrument Model LS-75 Sonifier with a 1/2-inch probe at setting 4 for four 15-second intervals, while chilling the suspension in ice water during and between disruption. A 10-l. portion of the sonicate is mixed with 25 ul. of an 890A1() solution containing 500 Ecg. per ml. Controls containing antibiotic and buffer alone; and sonicated cells and buffer without antibiotic are also run. After incubation overnight at 280C., 10-l.
quantities are applied to Schleicher & Schuell No. 2043-B paper. Using 0.03M potassium phosphate buffer, pH 7.1, a voltage gradient of 50 volts/cm. is applied for 30 minutes. The paper is placed on a Staphyloccoccus aureus ATCC 6538P assay plate and incubated at 37"C. for 18 hours.
The assay plates are prepared as follows: an overnight growth of the assay organism,
Staphylococcus aureus ATCC 6538P, in nutrient broth plus 0.2% yeast extract is diluted with nutrient broth, plus 0.2% yeast extract to a suspension having 60% transmittance at a wavelength of 660 nm. This suspension is added to Difco nutrient agar supplemented with 2.0 g./l. Difco yeast extract at 47"C. to 48"C., to make a composition containing 33.2 ml. of the suspension per liter of agar. Forty ml. of this suspension is poured into 22.5 cm. x 22.5 cm. petri plates, and these plates are chilled and held at 40C. until used (5-day maximum).
In addition to the unchanged bioactive 890A,(, spot migrating 8 cm. toward the positive pole, a new bioactive spot due to desacetyl 890A,(, is found migrating 4 cm. toward the positive pole. Control incubation mixtures of antibiotic plus buffer, and of cell sonicate plus buffer, produce no bioactive material migrating 4 cm. toward the positive pole.
EXAMPLE 3
Preparation of Antibiotic 890Aso Two frozen vials each containing 2 ml. of MA-4638 inoculum are slowly thawed, and the contents aseptically transferred to two seed flasks each containing 500 ml. of C Medium.
The seed flask, which is a 2-liter, triple-baffled shake flask equipped with a side arm. is stoppered with cotton.
C Medium
Autolysed Yeast (Ardamine*) 10.0 g.
Glucose 10.0 g.
MgSO4 7H2O 0.05 g.
Phosphate Buffer** 2.0 ml.
Distilled Water 1000 ml.
pH adjusted to 6.5 with
NaOH before sterilization
*Ardamine: Yeast Products, Inc.
**Phosphate buffer solution:
KH2PO4 91.0 g.
Na2HPO4 95.0 g.
Distilled Water 1000 ml.
The inoculated seed flasks are shaken for 24-30 hours at 280C t 1"C. on a 210 rpm gyrotory shaker, 2-inch throw.
The growth from the seed flasks are used to inoculate two 14-liter glass fermentors containing 10 liters of production medium (D medium plus 0.15% soybean oil, v/v).
D Medium
Dextrin (CPC Modified Starch) 40.0 g.
Distiller's Solubles 7.0 g.
Yeast Extract 5.0 g.
CoCl2 6H2O 50.0 mg.
Distilled Water 1000 ml.
pH adjusted to 7.3 with
NaOH before sterilization
The fermentors are operated at 24"C. using an agitation rate of 640 rpm (about Kd 5.5), and an air flow of 0.5 VVM, for 72 hours. Defoamer, Hodag-MF (Hodag Chemical Corp.) is used as required, but not to exceed 0.1%.
Contents of the two fermentors are pooled after the fermentation run, about 20 liters.
200-ml. portions of the batch are centrifuged in a Servall RC-2B centrifuge at 9000 rpm for 20 minutes. The supernatant is filtered through a 1-cm. bed of Hyflo Super-Cel in a 13-inch Lapp funnel with a cloth filter. The filtrate has a bioactiyity of 20 units/ml.
The filtered broth, (18 liters) is applied to a column (8.2 x 29 cm.) of Dowex-lx2(Cl-) 50-100 mesh, at 150 ml./min. The column is then washed with 1 liter of deionized water followed by 15 liters of 0.15 M NaCI + 0.01M Tris-HCl buffer, pH 7.0 + 25 FM neutral
EDTA in 50% MeOH at 150 ml./min.
The antibiotic 890A,(, is then eluted with 3.2% NaCI + 0.02 M Tris-HCl buffer pH 7.0 + 251lM neutral EDTA in 80% MEOH at 100 ml./min. Fractions are collected as follows: one fraction of 1 liter, four fractions of 500 ml. each, and twelve fractions of 1 liter each are collected . Bioactivity and absorbance at 220 nm is measured on each fraction, and those fractions leaving bioactivity/A22(, ratios of greater than 0.6 units/A22(, unit, and which also contained more than 10% of the total recovered activity per fraction are combined for further purification. Thus, fractions 4 to 8 are combined, containing a total of 22% of the applied bioactivity.
The pooled fractions are concentrated under reduced pressure to 190 ml., the precipitated salt is washed with deionized water, and the wash is added to the supernatant, bringing the final volume to 220 ml. The concentrate is adjusted to pH 6.5 with HC1 and is applied on a column (6.0 x 59 cm.) of Amberlite XAD-2 which has been previously washed with 8 liters of 60% aqueous acetone followed by 16 liters of deionized water. After application is completed, the column is rinsed with 5 x 10 ml. portions of deionized water, and the antibiotics are eluted with deionized water at 35 ml./min. Frac
Claims (23)
1. The compound desacetyl 890A1(), which has the formula
and its pharmaceutically acceptable salts.
2. A process for producing desacetyl 890A,(,
that comprises intimately contacting the compound 890A10, which has the formula
with an enzyme capable of hydrolysing the N-acetyl group.
3. A process as claimed in Claim 2 in which the enzyme is an amidohydrolase.
4. A process as claimed in Claim 3 in which the amidohydrolase is an Nacetylethanolamine amidohydrolase.
5. A process as claimed in Claim 3 in which the amidohydrolase is an N-acetyl 890A,o amidohydrolase.
6. A process for producing desacetyl 890A,o comprising obtaining microorganisms with N-acetyl-890A,o amidohydrolase by selecting those microorganisms capable of using
N-acetyl-ethanolamine for growth, testing these microorganisms for the presence of N-acetyl-890Alo amidohydrolase, and using the microorganisms with N-acetyl-890A amidohydrolase in a process as claimed in Claim 2 by intimately contacting them with the compound 890A,(,.
7. A process as claimed in Claim 3 carried out with an amidohydrolase produced by an amidohydrolase-producing strain of the microorganism Protaminobacter ruber.
8. A process for producing desacetyl 890A,(, that comprises intimately contacting 890A,o with the enzyme N-acetyl-890A,(, amidohydrolase produced by an amidohydrolaseproducing strain of the microorganism Protaminobacter rube.
9. A composition comprising an antibacterially effect amount of the compound desacetyl 890A,(, according to Claim 1 and a non-toxic pharmaceutically acceptable carrier.
10. A composition comprising an antibacterially effective amount of the compound claimed in Claim 1 and a carrier or diluent.
11. A composition as claimed in Claim 10 in the form of a disinfectant containing 0.1 to 1.00 ppm of the said compound.
12. A composition as claimed in Claim 9 also containing another antibiotic or pharmacologically active substance.
13. A composition as claimed in Claim 12, in which the other antibiotic or pharmacologically active substance is gentamycin, diphenoxylate or atropine.
14. A composition as claimed in Claim 9, 12 or 13 in the form of a capsule, tablet, powder, liquid solution, suspension, elixir, syrup or emulsion.
15. A composition as claimed in Claim 9, 12 or 13 in the form of a suppository.
16. A composition as claimed in Claim 9, 12 or 13 in injectable form.
17. A composition as claimed in Claim 9, 12 or 13 in the form of a throat spray, an inhalant, a lozenge or a throat paint.
18. A composition as claimed in Claim 9, 12 or 13 in topically administrable form.
19. A composition as claimed in Claim 18 in the form of an ointment, cream, lotion our paint.
20. A composition as claimed in Claim 10 in the form of a preparation suitable for administration in veterinary medicine.
21. A composition as claimed in Claim 20 in the form of an intramammary preparation.
22. A process as claimed in Claim 2 substantially as hereinbefore described in Example
23. A compound as claimed in Claim 1 when prepared by a process as claimed in any one of Claims 2 to 8 and 22.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76772377A | 1977-02-11 | 1977-02-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
GB1595234A true GB1595234A (en) | 1981-08-12 |
Family
ID=25080357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB5077/78A Expired GB1595234A (en) | 1977-02-11 | 1978-02-08 | Thienamycin derivatives |
Country Status (10)
Country | Link |
---|---|
JP (1) | JPS53101395A (en) |
CH (1) | CH637960A5 (en) |
DE (1) | DE2805701A1 (en) |
DK (1) | DK40578A (en) |
ES (1) | ES466646A1 (en) |
FR (1) | FR2380280A1 (en) |
GB (1) | GB1595234A (en) |
IT (1) | IT7847912A0 (en) |
NL (1) | NL7800957A (en) |
SE (1) | SE7800978L (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7800958A (en) * | 1977-02-11 | 1978-08-15 | Merck & Co Inc | ANTIBIOTIC DESACETYL-DIHYDRO 890 A9, METHOD FOR PREPARING IT AND PHARMACEUTICAL PREPARATION CONTAINING THIS ANTIBIOTIC. |
US4880793A (en) * | 1978-07-24 | 1989-11-14 | Merck & Co., Inc. | Combination of thienamycin-type antibiotics with dipeptidase inhibitors |
PH16708A (en) | 1978-07-24 | 1984-01-20 | Merck & Co Inc | Z-2-acylamino-3-monosubstituted propenoates |
DE2966187D1 (en) * | 1978-08-23 | 1983-10-27 | Beecham Group Plc | Beta-lactam antibacterial compounds, their preparation and pharmaceutical compositions containing them |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK497476A (en) * | 1975-11-24 | 1977-05-25 | Merck & Co Inc | PROCEDURE FOR THE PREPARATION OF AN ANTIBIOTIC SUBSTANCE |
NL7800958A (en) * | 1977-02-11 | 1978-08-15 | Merck & Co Inc | ANTIBIOTIC DESACETYL-DIHYDRO 890 A9, METHOD FOR PREPARING IT AND PHARMACEUTICAL PREPARATION CONTAINING THIS ANTIBIOTIC. |
-
1978
- 1978-01-26 SE SE7800978A patent/SE7800978L/en unknown
- 1978-01-26 NL NL7800957A patent/NL7800957A/en not_active Application Discontinuation
- 1978-01-27 DK DK40578A patent/DK40578A/en not_active Application Discontinuation
- 1978-02-03 IT IT7847912A patent/IT7847912A0/en unknown
- 1978-02-03 ES ES466646A patent/ES466646A1/en not_active Expired
- 1978-02-06 CH CH130878A patent/CH637960A5/en not_active IP Right Cessation
- 1978-02-08 GB GB5077/78A patent/GB1595234A/en not_active Expired
- 1978-02-09 FR FR7803666A patent/FR2380280A1/en active Granted
- 1978-02-10 DE DE19782805701 patent/DE2805701A1/en not_active Withdrawn
- 1978-02-13 JP JP1527878A patent/JPS53101395A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
FR2380280B1 (en) | 1980-05-16 |
CH637960A5 (en) | 1983-08-31 |
IT7847912A0 (en) | 1978-02-03 |
JPS53101395A (en) | 1978-09-04 |
ES466646A1 (en) | 1980-12-16 |
DK40578A (en) | 1978-08-12 |
SE7800978L (en) | 1978-08-12 |
FR2380280A1 (en) | 1978-09-08 |
DE2805701A1 (en) | 1978-08-17 |
NL7800957A (en) | 1978-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3950357A (en) | Antibiotics | |
US4168202A (en) | Process for producing antibiotics | |
US4162323A (en) | Antibiotic N-acetyl-dehydro-thienamycin | |
US4006060A (en) | Thienamycin production | |
US4162324A (en) | Antibiotics 890A1 and 890A3 | |
Kuroda et al. | FR-900130, a novel amino acid antibiotic I. discovery, taxonomy, isolation, and properties | |
GB1595234A (en) | Thienamycin derivatives | |
EP0001567B1 (en) | Thienamycin related antibiotics ps-6 and ps-7, process for their production and compositions containing them | |
GB1561108A (en) | Desacetyl antibiatics 890a1 and 890a3 | |
US4282322A (en) | Process for enzymatic deacylation of antibiotics | |
US4264734A (en) | Process for producing antibiotic desacetyl 890A10 | |
IL36281A (en) | Cephalosporin derivatives antibiotic mixtures containing them and process for their preparation | |
US4235967A (en) | Process for producing antibiotics by cultivation of Streptomyces flavogriseus | |
GB1561109A (en) | Antibiotics 890a1 and 890a3 | |
US4003902A (en) | Naphthyridinomycin antibiotics | |
US4304867A (en) | Culture of Streptomyces cattleya | |
US4264736A (en) | Antibiotic 890A10 | |
US4205068A (en) | β-Lactamase inhibitor EM4615 | |
US4656262A (en) | 7-methoxy cephalosporin derivative | |
GB1592807A (en) | Production of an antibiotic | |
US4081548A (en) | Antibiotics | |
JPH0430400B2 (en) | ||
GB1595233A (en) | Production of an antibiotic | |
GB1561107A (en) | N-acetyl thienamycin | |
Cassidy et al. | Antibiotics 890A 1 and 890A 3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PS | Patent sealed [section 19, patents act 1949] | ||
PCNP | Patent ceased through non-payment of renewal fee |